Aspen Neuroscience to Present at 2020 Virtual Cell & Gene Meeting on the Mesa


SAN DIEGO, October 5, 2020 — Aspen Neuroscience announced today that Howard Federoff, MD, PhD, Chief Executive Officer, will present at the annual Cell & Gene Meeting on the Mesa to be held virtually October 12-16, 2020.

Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a five-day virtual conference featuring more than 120 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies. The meeting also includes over 100 panelists and featured speakers taking part in 20 in-depth sessions covering all aspects of cell and gene therapy commercialization.

The following are specific details regarding Aspen’s presentation at the conference:

  • Event: 2020 Virtual Cell & Gene Meeting on the Mesa
  • Date: Monday, October 12 – Friday, October 16
  • Time: Company presentations will be available to view on-demand throughout the entirety of the conference

Please visit www.meetingonthemesa.com for full information including registration. Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors should contact Laura Stringham at lstringham@alliancerm.org and interested media should contact Kaitlyn Dupont at kdupont@alliancerm.org.


ABOUT ASPEN NEUROSCIENCE

Aspen Neuroscience, Inc., is a development stage, private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson disease. We strive to develop best-in-class methods for autologous neuron replacement using induced-pluripotent stem cells (iPSCs) to address diseases with high unmet clinical need beginning with Parkinson disease and extending across the brain and affected organs. For more information and important updates, please visit aspenneuroscience.com


Please note that we at Aspen Neuroscience do not make determinations on who would be eligible for participation in clinical trials, and we do not offer tours of our laboratory. At this time, our therapy has not yet been used in humans and clinical trials have not begun.